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Determining when to take science from the bench to the bedside requires careful review of specific research advances, often
incremental, as well as rigorous ethical and logistical planning. In this vein, one of themajor initiatives that the ISSCRundertook
in 2010was the launch of its ‘‘ACloser Look at StemCell Treatments’’ website,which features prominently in theAnnual Report
that is published thismonth. Several researchpapers in this issue report basic findings that seempoised tomove the field closer
to therapeutic development, but one in particular offers the type of safety detail and technical support that is needed to move
forward to clinical application. Described in our inaugural Clinical Progress article, North and colleagues apply their earlier
finding that exposure todimethyl-prostaglandinE2expands functionalHSCs tohumanxenotransplantsandnonhumanprimate
models and demonstrate the safety of this system. As they discuss, these findings have provided sufficient support to move
forward to a Phase I clinical trial. Lee and colleagues use a reporter mousemodel to show that functional cardiac improvement
observed following the transfer of donor c-kit+ BMprogenitors is due to activation of an endogenousprogenitor. Understanding
thismechanismof actionmight help fine-tuneongoingclinical
trials that follow similar paradigms but that have thus far had
limited success. On the cancer front, Liu and coauthors find
that inhibition of hypoxia-inducible factor can selectively
targethuman leukemia inaxenograftmodel in away thatpref-
erentially eliminates the tumor cells. Future efforts to develop
clinically relevant inhibitors for this pathway may help target
cancer stem cells while preserving normal HSC function.
Pluripotent Promise
Recentpublications inCellStemCellandelsewherehavehigh-
lighted that bothESCand iPSC lines harbor geneticandepige-
netic aberrations. In their Preview, Izpisua Belmonte and
colleagues overview this work and share their views on the
growing debate over whether the presence of thesemodifica-
tions will preclude future clinical or research use of pluripotent cell lines. It is possible that alternate protocols will generate iPSCs
free of these aberrations, andMorrisey and colleagues demonstrate that a specificmiRNA cluster, miR302/367, is sufficient—on
itsown—to lead toefficientderivationofbothmouseandhuman iPSCs. It seems likely that the rapidlyexpandingnumberofplurip-
otent cell lines will continue to grow, and Luong and colleagues outline a proposed plan for adjusting the nomenclature used to
designate newly published iPSCs and ESCs, to promote discussion in the field that, they hope, will result in a central registry of
uniquenamesused to identify distinct lines in the literature.Nomatterwhatdesignation is applied to individual cell lines, thepower
of pluripotent cells stems from their capacity to differentiate into cells of any embryonic germ layer. In their Perspective article, Loh
and Lim offer an explanation as to how ESCsmanage to exhibit this diverse lineage potential while still maintaining an undifferen-
tiatedphenotype.Theypropose thatat least some transcription
factors that predominate in pluripotent cells, such as Oct4,
Nanog, and Sox2, are in fact lineage specifiers with competing
specificities, and that, rather than being a stable state, pluripo-
tency is, in fact, a rather precarious balance between the
opposing activities of these different factors. While rooted in
publisheddata, theirmodel awaits further testing andpromises
to open interesting discussion among the field.
Valuing Human ESCs
While not yet ready for the clinic, findings from Martinat and
coauthors offer a striking example of how human ESC studies
can provide otherwise inaccessible insights into disease
pathology and candidate therapy design. Specifically, they
use a myotonic dystrophy 1 (DM1) mutation-bearing hESC
line to uncover a developmental defect in neurite formation. Without ready access to patient neural tissue, mechanistic studies
of this condition have focused primarily onmuscle defects. However, by using the hESC system, the authors reveal that neuro-
muscular connections are altered inDM1and that twoSLITRK family genes identified in themutant culturedneural cells are also
misexpressed inpatient-brainbiopsies, offeringa candidatepathway formorespecific investigation in aclinical setting.Accord-
ing to most specialists, the capacity to derive new hESC lines remains an important goal of the field, and to do so, human
embryosmust be obtained for research purposes. Scott and coauthors present a Forum article describing a two-stage embryo
donation consent procedure in place at Stanford University. By allowing embryo donors to peruse information pamphlets at
homeand tocontact the research institutionon their ownafter their reproductiveproceduresarecomplete, thisprotocol assures
that appropriate consent measures are in place while also increasing the availability of ethically acquired human embryos for
research. Their paradigm may offer a valuable resource to other groups and institutions working in collaboration with fertility
clinics and embryo storage facilities.Cell Stem Cell 8, April 8, 2011 ª2011 Elsevier Inc. xi
